<SEC-DOCUMENT>0001171843-12-003201.txt : 20120824
<SEC-HEADER>0001171843-12-003201.hdr.sgml : 20120824
<ACCEPTANCE-DATETIME>20120824072746
ACCESSION NUMBER:		0001171843-12-003201
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20120824
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120824
DATE AS OF CHANGE:		20120824

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			THERAVANCE INC
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30319
		FILM NUMBER:		121053169

	BUSINESS ADDRESS:	
		STREET 1:		901 GATEWAY BLVD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508086000

	MAIL ADDRESS:	
		STREET 1:		901 GATEWAY BLVD
		CITY:			S. SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>document.htm
<DESCRIPTION>FORM 8-K FILING DOCUMENT
<TEXT>
<html>

	<head>
		<title>Form 8-K Filing</title>
	</head>

	<body>
		<p align="center"><b>UNITED STATES</b><br>
			<b>SECURITIES AND EXCHANGE COMMISSION</b><br>
			<b>Washington, D.C. 20549</b><br>
		</p>
		<p align="center"><b>FORM 8-K</b></p>
		<p align="center"><font size="2"><b>Current Report Pursuant<br>
					to Section 13 or 15(d) of the<br>
					Securities Exchange Act of 1934</b></font></p>
		<p align="center"><font size="2">Date of Report (Date of earliest event Reported): August 24, 2012</font></p>
		<p align="center"><font size="4"><b>THERAVANCE, INC.</b></font><br>
			<font size="2">(Exact Name of Registrant as Specified in its Charter)</font></p>
		<!-- Registrant's State of Inc, File and IRS Number -->
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="32%" align="center"><font size="2"><b>Delaware</b></font></td>
				<td width="3%"><font size="2">&nbsp;</font></td>
				<td width="32%" align="center"><font size="2"><b>000-30319</b></font></td>
				<td width="3%"><font size="2">&nbsp;</font></td>
				<td width="32%" align="center"><font size="2"><b>94-3265960</b></font></td>
			</tr>
			<tr valign="top">
				<td width="32%" align="center"><font size="2">(State or Other Jurisdiction of Incorporation) </font></td>
				<td width="3%"><font size="2">&nbsp;</font></td>
				<td width="32%" align="center"><font size="2">(Commission File Number) </font></td>
				<td width="3%"><font size="2">&nbsp;</font></td>
				<td width="32%" align="center"><font size="2">(I.R.S. Employer Identification Number) </font></td>
			</tr>
		</table>
		<!-- Registrant's Postal Addess and Zip Code --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="bottom">
				<td width="47%" align="center"><font size="2"><b>901 Gateway Boulevard<br>
South San Francisco, California 94080 <br>
					(650) 808-6000</b></font></td>
			</tr>
			<tr valign="top">
				<td width="47%" align="center"><font size="2">(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)</font></td>
			</tr>
		</table>
		<p align="center"><br>
			<!--<font size="2"><b>________________________________________________________________________________</b><br>
			(Former name or former address, if changed since last report)</font><font size="2"><b></b></font>--></p>
		<!-- Simultaneous filing obligation checkboxes --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td colspan="3"><font size="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):<br>
						<br>
					</font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></td>
			</tr>
		</table>
		<br>
		<hr noshade="1">
		<font size="2"></font>
		<p><b><p><font size="3"><b>Item 7.01. Regulation FD Disclosure.</b></font></p></b></p>
		<p><font size="2"><p>
	<i>The information contained in this Item 7.01 and in the accompanying exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</i><font size="+0"> <br />
	</font><br />
	On August 24, 2012, GlaxoSmithKline (GSK) and Theravance, Inc. (the &quot;Company&quot;) issued a press release announcing the completion of the Phase 3 program of an investigational LAMA/LABA in patients with chronic obstructive pulmonary disease (COPD). LAMA/LABA is a combination of two investigational bronchodilator molecules &ndash; umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long&#8209;acting beta<sub>2</sub> agonist (LABA), currently in development under the LABA collaboration agreement with GSK and the Company, for the treatment of COPD. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.</p>
</font></p>
		<font size="2"></font>
		<p><b><p><font size="3"><b>Item 9.01. Financial Statements and Exhibits.</b></font></p></b></p>
		<p><font size="2"><p>
	 </p>
<table border="0" cellpadding="0" cellspacing="0">

		<tr>
			<td valign="top" width="62">
				<p>
					(d)</p>
			</td>
			<td valign="top" width="101">
				<p>
					Exhibits.</p>
			</td>
			<td valign="top" width="475">
				<p>
					 </p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="62">
				<p>
					 </p>
			</td>
			<td valign="top" width="101">
				<p>
					 </p>
			</td>
			<td valign="top" width="475">
				<p>
					 </p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="62">
				<p>
					 </p>
			</td>
			<td valign="top" width="101">
				<p>
					<b><u>Exhibit</u></b></p>
			</td>
			<td valign="top" width="475">
				<p>
					<b><u>Description</u></b></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="62">
				<p>
					 </p>
			</td>
			<td valign="top" width="101">
				<p>
					 </p>
			</td>
			<td valign="top" width="475">
				<p>
					 </p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="62">
				<p>
					 </p>
			</td>
			<td valign="top" width="101">
				<p>
					Exhibit 99.1</p>
			</td>
			<td valign="top" width="475">
				<p>
					Press Release of Theravance, Inc. dated August 24, 2012</p>
			</td>
		</tr>

</table>
</font></p>
		<hr noshade="1">
		<!-- Registrant's Signature -->
		<p align="center"><b><font size="2">SIGNATURE</font></b></p>
		<p><font size="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="47%"><font size="2">&nbsp;</font></td>
				<td width="5%"><font size="2">&nbsp;</font></td>
				<td style="text-transform: uppercase" width="47%"><font size="2"><b>THERAVANCE, INC.</b><br>
					<br>
					</font></td>
			</tr>
			<tr valign="top">
				<td width="47%">
					<p><font size="2">Date: August 24, 2012</font></p>
				</td>
				<td width="5%"><font size="2">&nbsp;</font></td>
				<td width="47%"><font size="2"><b><u>/s/<!--MICHAEL W. AGUIAR--> Michael W. Aguiar</u></b><br>
					Michael W. Aguiar<br>
					Chief Financial Officer</font></td>
			</tr>
		</table>
		<font size="2"><hr />
<p align="center">
	<strong>EXHIBIT INDEX</strong></p>
<p align="center">
	 </p>
<p>
	 </p>
<table border="0" cellpadding="0" cellspacing="0">

		<tr>
			<td valign="top" width="101">
				<p>
					<b><u>Exhibit</u></b></p>
			</td>
			<td valign="top" width="475">
				<p>
					<b><u>Description</u></b></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="101">
				<p>
					 </p>
			</td>
			<td valign="top" width="475">
				<p>
					 </p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="101">
				<p>
					Exhibit 99.1</p>
			</td>
			<td valign="top" width="475">
				<p>
					Press Release of Theravance, Inc. dated August 24, 2012</p>
			</td>
		</tr>

</table></font>
	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>newsrelease.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD</title></head><body><p align="right">EXHIBIT 99.1</p><h3 align="center">GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD</h3><h4 align="center">GSK Confirms Its Intention to Commence Global Filings From the End of 2012</h4><p>LONDON and SOUTH SAN FRANCISCO, Calif., Aug. 24, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease (COPD).</p><p>
	LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta<sub>2</sub> agonist (LABA), administered using the ELLIPTA&#8482; inhaler. UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.</p><p>
	On 2 July 2012, GSK and Theravance announced the completion of four pivotal studies for UMEC/VI. The pivotal programme for UMEC/VI also includes a 52-week safety study, which is now complete. Two non-pivotal 12-week crossover exercise studies will also be included in the registrational package as they are now also complete.<strong> </strong>These recently completed studies support GSK's plans to commence global regulatory submissions for UMEC/VI from the end of 2012. &#160;</p><p>
	The full results of all these studies, together with additional data from phase IIb dose-ranging studies of UMEC, will be presented at future scientific meetings.</p><p>
	<strong>About the LAMA/LABA Studies</strong></p><p>
	The 52-week parallel group safety study evaluated the long-term safety and tolerability of UMEC 125mcg alone and the combination UMEC/VI 125/25mcg compared to placebo in approximately 500&#160;patients. The two replicate 12&#8209;week crossover exercise studies of approximately 300 patients each, evaluated the lung function and exercise endurance time of UMEC/VI 125/25mcg and 62.5/25mcg, UMEC 125mcg and 62.5mcg, and VI 25mcg compared to placebo. The co-primary endpoints of these studies were 3&#8209;hour post-dose exercise endurance time and trough FEV1.</p><p>
	<strong>Other Respiratory Development Programmes</strong></p><p>
	The data from these studies will also contribute to the future regulatory submissions for GSK's UMEC monotherapy, with global filings commencing in 2013.</p><p>
	UMEC/VI is one of several late-stage assets in the GSK respiratory development portfolio, which includes fluticasone furoate/vilanterol (FF/VI, with proposed brand names RELVAR&#8482; and BREO&#8482;), VI monotherapy and MABA (GSK961081), developed in collaboration with Theravance, as well as GSK's investigational medicines FF monotherapy, UMEC monotherapy and anti-IL5 MAb (mepolizumab). These investigational medicines are not currently approved anywhere in the world.</p><p>
	<strong>GlaxoSmithKline &#8211;</strong> one of the world's leading research-based pharmaceutical and healthcare companies &#8211; is committed to improving the quality of human life by enabling people to do more, feel better and live longer.&#160;For further information please visit www.gsk.com.</p><p>
	<strong>Theravance</strong> &#8211; is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programs include:&#160;RELVAR&#8482; or BREO&#8482; (FF/VI), umeclidinium bromide/vilanterol (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit Theravance's web site at www.theravance.com.</p><p>
	THERAVANCE&#174;, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE&#174; are registered trademarks of Theravance, Inc.</p><p>
	RELVAR&#8482;, BREO&#8482; and ELLIPTA&#8482; are trademarks of the GlaxoSmithKline group of companies. The use of these brand names has not yet been approved by any regulatory authority.</p><p>
	<strong>Cautionary statement regarding forward-looking statements<strong><br>
	</strong></strong><br>
	Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2011.</p><p>
	<strong>Theravance forward-looking statement</strong></p><p>
	This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to the timing of data analysis and communication of results from clinical studies, statements regarding the potential benefits and mechanisms of action of drug candidates, statements concerning the timing of seeking regulatory approval of our product candidates, statements concerning enabling capabilities of Theravance's approach to drug discovery and its proprietary insights, and statements concerning expectations for product candidates through development and commercialization. These statements are based on the current estimates and assumptions of the management of Theravance as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in its forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, the potential that results of clinical or non-clinical studies indicate product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals for product candidates and risks of collaborating with third parties to develop and commercialize products. These and other risks are described in greater detail under the heading "Risk Factors" contained in Theravance's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 1, 2012 and the risks discussed in our other period filings with SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance assumes no obligation to update its forward-looking statements.</p><p>
	This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.</p><table cellpadding="0" cellspacing="6" style=" border-collapse: separate; border-spacing: 6px ">

		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>GlaxoSmithKline Enquiries:</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				UK Media enquiries:</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				David Mawdsley</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+44 (0) 20 8047 5502</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(London)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Stephen Rea</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+44 (0) 20 8047 5502</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(London)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Sarah Spencer</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+44 (0) 20 8047 5502</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(London)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				David Daley</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+44 (0) 20 8047 5502</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(London)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				US Media enquiries:</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Kevin Colgan</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+1 919 483 2933</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(North Carolina)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Melinda Stubbee</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+1 919 483 2510</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(North Carolina)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Sarah Alspach</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+1 202 715 1048</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(Washington, DC)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Jennifer Armstrong</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+1 215 751 5664</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(Philadelphia)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				<strong>&#160;</strong></td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Analyst/Investor enquiries:</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Sally Ferguson</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+44 (0) 20 8047 5543</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(London)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Tom Curry</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+ 1 215 751 5419</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(Philadelphia)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Gary Davies</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+ 44 (0) 20 8047 5503</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(London)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				James Dodwell</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+ 44 (0) 20 8047 2406</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(London)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Jeff McLaughlin</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+ 1 215 751 7002</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(Philadelphia)</td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Ziba Shamsi</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				+ 44 (0) 20 8047 3289</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(London)</td>
		</tr>

</table><table cellpadding="0" cellspacing="6" style=" border-collapse: separate; border-spacing: 6px ">

		<tr>
			<td colspan="4" style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				&#160;<br>
				<strong>Theravance Inc. Enquiries</strong></td>
		</tr>
		<tr>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Investor.relations@theravance.com</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				Michael W. Aguiar</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(650) 808 4100</td>
			<td style="font: 12px Arial; vertical-align: bottom; text-align: left ">
				(San Francisco)</td>
		</tr>

</table></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
